“This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device,” said Colin Kealey, M.D., President and CEO of NeuroSigma. "As we move into 2026, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback